Trial Profile
Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously as increasing single doses to healthy male volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2011
Price :
$35
*
At a glance
- Drugs RO 14 (Primary)
- Indications Thrombosis; Venous thromboembolism
- Focus Adverse reactions
- 01 Apr 2011 Results published in Thrombosis Research.
- 15 Jul 2009 Results presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
- 12 Jan 2009 Actual end date changed from Feb 2008 to Dec 2008 as reported by Clinicaltrials.gov.